June 28, 2018 08:50 AM EDT
People
R&D
Pharma

Sar­co­ma ex­pert George Demetri grades the lat­est state­ment on Nanobi­otix's late-stage drug NBTXR3

John Carroll

Editor & Founder

The first glance at Nanobi­otix’s re­cent round of da­ta for its drug NBTXR3 re­vealed pos­i­tive, but not pow­er­ful, da­ta when used against soft tis­sue sar­co­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times